1. Volume 120, Issue 7, Pages 1713-1719 (June 2001)
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth 
Moss Mann, Hongmiao Sheng, Jinyi Shao, Christopher S. Williams, Raymond N. Dubois 
Gastroenterology 
Volume 120, Issue 7, Pages (June 2001)
DOI: /gast
Copyright © 2001 American Gastroenterological Association Terms and Conditions

2. Fig. 1
Expression of ErbB/HER receptors and ligands in the HCA-7 carcinoma cell line. mRNA from exponentially growing HCA-7, MCF-7, or MDA-231 cells was used as a template for a real-time quantitative reverse-transcription polymerase chain reaction assay to measure relative levels of (A) ErbB receptor subtypes or (B) known ErbB ligands. (C) Whole-cell protein lysates from HCA-7 or HCT-116 cells were analyzed for HER2/neu levels by Western blot analysis.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

3. Fig. 2
The effects of the HER-2/neu ligand HRGβ-1 on the growth of HCA-7 cells. Exponentially growing HCA-7 cells were exposed to increasing doses of HRGβ-1. After 8 days, cells from each sample were counted using a Coulter counter. Data represent means from 3 independent experiments; error bars = SEM.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

4. Fig. 3
The effects of celecoxib or Herceptin on the growth of HRGβ-1–stimulated HCA-7 cells. Exponentially growing HCA-7 cells were exposed to 40 ng/mL of HRGβ-1 and treated with either 10 μmol/L celecoxib (CL), 10 μg/mL Herceptin (HER), or a combination of the 2. Each sample was normalized to contain equivalent amounts of both dimethyl sulphoxide and bacteriostatic water. Data represent means from 3 independent experiments; error bars = SEM. Differences between treated groups and controls were statistically significant (P = , CL vs. control; P = 0.002, comparing HER vs. control; P = , CL/HER vs. control).
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

5. Fig. 4
The effects of celecoxib or Herceptin on the growth of HCA-7 cells in Matrigel. CTL, control-treated cells; CEL, cells treated with 10 μmol/L celecoxib; HER, cells treated with 10 μg/mL of Herceptin; +, cells treated with 40 ng/mL of HRGβ-1. (A) The colony number of each experimental sample was counted using an inverted microscope. Data represent mean numbers of colonies from 9 independent fields/well. Differences between treated groups and controls were not statistically significant, except for CEL/HER (P = , CEL/HER vs. CTL). (B) The colony size of each sample was measured by projecting photographic images of each well and measuring the average size of the 3 largest colonies from each sample. In each case, the data represent the means from 3 independent experiments; error bars = SEM. The effects of CEL (P = ) and CEL/HER (P = ) were statistically significant compared with controls. HER treatment did not have a significant effect when given alone, probably because of its poor diffusion into the matrix surrounding the cells.
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions

6. Fig. 5
The effects of celecoxib, Herceptin, or 2C4 on the growth of HCA-7 cells in vivo. HCA-7 cells (1.1 × 106) were subcutaneously injected into the dorsal flank of athymic mice. Approximately 11 days after tumor injection (when the mean tumor volume had reached 138 mm3), mice were randomly divided into the different treatment groups. (A) Mice were treated with celecoxib at a dose of 1250 mg/kg chow, 20 mg/kg body weight of Herceptin (delivered via peritoneal injection twice a week), or a combination of the 2 drugs. The difference in growth between celecoxib- and Herceptin-treated and control animals was statistically significant (P = ); there was no significant difference with either agent alone; however, the combination of celecoxib and Herceptin was more effective than either agent alone (P = ). (B) Mice were treated with celecoxib as described above and/or with 2C4 delivered via peritoneal injection twice a week at a dose of 20 mg/kg body weight. Tumors were measured twice weekly using a digital caliper. Tumor volumes were calculated using the equation V = [L × W2] × 0.5 (V, volume; L, length; W, width). Data from each treatment group represent the means from 7 mice; error bars = SEM. There was a statistically significant difference between all treated groups and controls (P = ).
Gastroenterology  , DOI: ( /gast )
Copyright © 2001 American Gastroenterological Association Terms and Conditions